Summit achieving its first research target in its exclusive strategic alliance with the University of Oxford is very encouraging. The positive development follows the recent extension of the alliance until at least November 2019 and highlights the value of Summit’s relationship with the University. The group’s lead utrophin modulator, SMT C1100, is due to commence a Phase II open label trial imminently. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europ ....
